Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100115 | 0.98 | CES2 (0.45) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL10775693 | 0.81 | HPGD (0.32) | CA12CA9CA14 | |
| SCHEMBL1583684 | 0.77 | CES2 (0.40) | CES2CES1CA12CA9 | |
| SCHEMBL1584057 | 0.76 | CES2 (0.40) | CES2CES1PARP1HDAC1HDAC6 | |
| SCHEMBL7515944 | 0.74 | PARP1 (0.41) | PARP1IDO1MGLLMMP2CA14 | |
| SCHEMBL7514462 | 0.74 | FAAH (0.34) | IDO1FAAHMGLL | |
| SCHEMBL1466275 | 0.74 | CYP1A2 (0.44) | PARP1MEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL1585001 | 0.74 | ACHE (0.46) | PARP1HDAC6ACHEMEN1KMT2A | |
| SCHEMBL18434981 | 0.74 | HDAC8 (0.45) | MEN1KMT2AHDAC4MGLL | |
| SCHEMBL10344609 | 0.74 | CES2 (0.42) | CES2CES1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | Oxford Drug Design Limited (GB) | 2023-10-31 | — | — | US | disclosed |
| US-20200039929-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | INHIBOX LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| EP-3523282-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | Oxford Drug Design Limited (GB) | 2019-08-14 | — | — | EP | disclosed |
| US-20190135777-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-05-09 | — | — | US | disclosed |
| US-10160744-B2 | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-12-25 | — | — | US | disclosed |
| WO-2018065611-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | Oxford Drug Design Limited (GB) | 2018-04-12 | — | — | WO | disclosed |
| CN-107540586-A | A kind of preparation method of the thioaryl sulphonic acid ester of difluoromethyl substitution | 中国科学院上海有机化学研究所 | 2018-01-05 | — | — | CN | disclosed |
| CN-105985274-B | Thioaryl sulphonic acid ester, its preparation method and the application of difluoromethyl substitution | 中国科学院上海有机化学研究所 | 2017-11-07 | — | — | CN | disclosed |
| US-20170260158-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-09-14 | — | — | US | disclosed |
| CN-105985274-A | Difluoromethyl-substituted sulfoaryl sulfonate, and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2016-10-05 | — | — | CN | disclosed |
| WO-2012099952-A2 | BENZOFURO[3,2-C] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184531-A1 | BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011044134-A1 | EPIMINOCYCLOALKYL(B)INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| CN-101801962-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| EP-1231197-A1 | Process for producing allyl halide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-14 | — | — | EP | disclosed |
| US-20020107422-A1 | Process for producing allyl halide compound | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | HTR6, HTR3B, HTR1B | CES2 213/4885CES1 178/4885PARP1 4138/4885 |
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | CES2 2150/4885CES1 2220/4885PARP1 1146/4885 |
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | AARS1, NSUN3, GARS1 | CES2 1372/4885CES1 1245/4885PARP1 2614/4885 |
| US-20200039929-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | AARS1, NSUN3, GARS1 | CES2 1372/4885CES1 1245/4885PARP1 2614/4885 |
| US-20170260158-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR5A, HTR1A | CES2 950/4885CES1 1688/4885PARP1 2661/4885 |
| US-10160744-B2 | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor | HTR6, HTR5A, HTR1A | CES2 950/4885CES1 1688/4885PARP1 2661/4885 |
| US-20120184531-A1 | BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA | HTR6, HTR5A, HTR2C | CES2 826/4885CES1 449/4885PARP1 3525/4885 |
| US-20020107422-A1 | Process for producing allyl halide compound | ENY2, ZYX, RPS4Y1 | CES2 1967/4885CES1 1097/4885PARP1 779/4885 |
| US-20190135777-A1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR5A, HTR1A | CES2 950/4885CES1 1688/4885PARP1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.